Colorectal Cancer

Targeting KRAS in Colorectal Cancer Is an Ongoing Medical Challenge

October 01, 2020

Due to the high prevalence of KRAS-mutant colorectal cancer and the fact that many different KRAS variants are found in these tumors, developing treatment for patients with KRAS-mutant colorectal cancer is an area of unmet medical need

Improvements Seen in Health-Related QoL With First Line Pembrolizumab for DNA Repair-Deficient Metastatic CRC

September 19, 2020

The health-related quality of life had clinically meaningful improvements with pembrolizumab as a first-line therapy for patients with microsatellite instability-high and/or mismatch repair-deficient metastatic colorectal cancer versus standard-of-care chemotherapy, according to new data presented at the ESMO Virtual Congress 2020.

Black Patients Experience Lower OS With CRC Liver Metastases Than Others

September 12, 2020

Compared to other racial and ethnic groups, Black patients were the least likely to receive chemotherapy or surgical resection for colorectal liver metastases and experienced worse survival, according to a published research paper.

Liquid Biopsy Assay May Be Predictive of Survival With Rechallenging Anti-EGFR Treatment in mCRC

September 01, 2020

RAS status detected in circulating tumor DNA was associated significantly with clinical outcomes when patients with metastatic colorectal cancer were rechallenged with anti-EGFR monoclonal antibody therapy of either cetuximab or panitumumab, according to findings from a clinical study evaluating RAS mutational status in ctDNA using the OncoBEAM RAS CRC test kit in 2 Japanese multicenter, prospective studies.

FDA Approves Frontline Pembrolizumab for MSI-H/dMMR CRC

June 29, 2020

"Patients with unresectable or metastatic MSI-H colorectal cancer have historically faced poor outcomes, and until today, chemotherapy-containing regimens were the only FDA-approved first-line treatment options."

Trastuzumab Deruxtecan Demonstrates Efficacy for mCRC in DESTINY-CRC01

June 29, 2020

Salvatore Siena, MD, discusses the efficacy of the phase 2 DESTINY-CRC01 trial of trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer who have progressed on 2 or more treatments in this setting.